Pulmonx® Acquires Assets of Aeris Therapeutics, Expanding the Company’s Treatment Options for COPD Patients
January 08, 2015 08:00 AM Eastern Standard Time
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Pulmonx®, a leader in interventional pulmonology, today announced its acquisition of the assets of Aeris Therapeutics, maker of AeriSeal®, a foam-based lung sealant system for the treatment of emphysema, a form of chronic obstructive pulmonary disease (COPD). The addition of AeriSeal to the Pulmonx portfolio is expected to significantly expand the treatable patient population for the company’s therapies.
“We will be performing additional development work on AeriSeal to enhance its clinical profile and are confident that we will be able to deliver an effective treatment to physicians.”
Pulmonx offers the Zephyr® Endobronchial Valve (EBV), a minimally invasive treatment for severe emphysema that has been proven over a decade of clinical experience to significantly improve the lung function, exercise tolerance and quality of life for patients receiving treatment. A proprietary diagnostic is run prior to the procedure to identify likely responders with a high degree of certainty. In the procedure, tiny, one-way valves are placed in the lungs to block airflow to diseased regions to achieve lung volume reduction. As a result, the remaining healthy regions may function more efficiently, enabling better breathing and an improved quality of life. More than 25,000 Zephyr EBVs have been implanted globally.
The AeriSeal treatment uses a foam sealant to block diseased regions in the lung to achieve volume reduction and improve breathing function. The treatment is independent of collateral ventilation and is designed for patients with heterogeneous and homogeneous emphysema, thereby enlarging the patient pool for Pulmonx’ therapies. AeriSeal is delivered in a simple procedure that does not require evaluation of available lung tissue or tissue integrity. AeriSeal is expected to be commercially available in Europe upon reissuance of the CE Mark, which is expected in the second half of 2015.
“Our Zephyr EBV device has been proven to significantly and predictably improve symptoms in certain advanced emphysema patients. By adding AeriSeal to our portfolio, we will be filling a treatment gap, enabling us to treat almost the entire spectrum of advanced emphysema patients,” said Pulmonx Chief Executive Officer Glen French. “We will be performing additional development work on AeriSeal to enhance its clinical profile and are confident that we will be able to deliver an effective treatment to physicians.”
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com